2seventy bio Inc (TSVT) concluded trading on Thursday at a closing price of $4.98, with 0.44 million shares of worth about $2.21 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 0.40% during that period and on April 17, 2025 the price saw a gain of about 0.20%. Currently the company’s common shares owned by public are about 51.59M shares, out of which, 47.46M shares are available for trading.
Stock saw a price change of 0.40% in past 5 days and over the past one month there was a price change of 0.40%. Year-to-date (YTD), TSVT shares are showing a performance of 69.39% which increased to 2.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.29 but also hit the highest price of $5.30 during that period. The average intraday trading volume for 2seventy bio Inc shares is 1.24 million. The stock is currently trading 0.53% above its 20-day simple moving average (SMA20), while that difference is up 27.53% for SMA50 and it goes to 24.17% higher than SMA200.
2seventy bio Inc (NASDAQ: TSVT) currently have 51.59M outstanding shares and institutions hold larger chunk of about 99.16% of that.
The stock has a current market capitalization of $260.64M and its 3Y-monthly beta is at 1.00. It has posted earnings per share of -$1.12 in the same period. It has Quick Ratio of 4.67 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TSVT, volatility over the week remained 0.44% while standing at 0.49% over the month.
Stock’s fiscal year EPS is expected to rise by 63.64% while it is estimated to increase by 63.13% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on June 06, 2024 offering a Sell rating for the stock and assigned a target price range of between $5 and $2 to it. Coverage by Leerink Partners stated 2seventy bio Inc (TSVT) stock as an Outperform in their note to investors on January 31, 2024, suggesting a price target of $18 for the stock. On January 31, 2024, TD Cowen Downgrade their recommendations, while on October 30, 2023, Leerink Partners Downgrade their ratings for the stock with a price target of $6. Stock get a Buy rating from Citigroup on October 12, 2023.
